Truist analyst Greg Fraser lowered the firm’s price target on Pacira to $63 from $68 but keeps a Buy rating on the shares. The analyst is adjusting his model to reflect continued headwinds for recovery of the elective surgery market, noting that while Exparel demand growth has outpaced market growth, Pacira recently highlighted "persistent headwinds" for the overall market, particularly for in-patient procedures. Fraser adds however that despite the ongoing headwinds for the elective surgery market, he remains bullish on the potential of Pacira’s non-opioid pain portfolio.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PCRX:
- Pacira price target lowered to $52 from $60 at BMO Capital
- Pacira price target lowered to $63 from $66 at Needham
- Pacira sees FY22 EPS ‘at least’ $2.50, consensus $2.77
- Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million
- Pacira price target lowered to $50 from $54 at Cowen